8-K Announcements
6Material company update
Apr 7, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 14, 2026·SEC
Nuvalent, Inc.(NUVL)Earnings, Financials & Key Ratios
NUVL•NASDAQ
$101.47
$6.74B mkt cap·Price updated May 6, 2026
AboutNuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA$0+100.0%
- Net Income-$261M-106.6%
- EPS (Diluted)-3.93-81.1%
- ROE-29.46%-35.8%
- ROIC-32.62%+14.7%
NUVL Key Insights
Nuvalent, Inc. (NUVL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 14.1% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NUVL Price & Volume
Nuvalent, Inc. (NUVL) stock price & volume — 10-year historical chart
Loading chart...
NUVL Growth Metrics
Nuvalent, Inc. (NUVL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-70.07%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-53.31%
Return on Capital
10 Years-151.57%
5 Years-151.57%
3 Years-26.69%
Last Year-31.36%
NUVL Recent Earnings
Nuvalent, Inc. (NUVL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)
Q1 2026Latest
Feb 26, 2026EPS
$1.29
Est $1.48
+12.8%
Revenue
—
Est $7M
Q4 2025
Oct 30, 2025EPS
$1.70
Est $1.39
-22.3%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$1.31
Est $1.27
-3.1%
Revenue
—
Q2 2025
May 8, 2025EPS
$1.18
Est $1.14
-3.5%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $1.29vs $1.48+12.8% | —vs $7M |
| Q4 2025 | Oct 30, 2025 | $1.70vs $1.39-22.3% | — |
| Q3 2025 | Aug 7, 2025 | $1.31vs $1.27-3.1% | — |
| Q2 2025 | May 8, 2025 | $1.18vs $1.14-3.5% | — |
Based on last 12 quarters of dataView full earnings history →
NUVL Peer Comparison
Nuvalent, Inc. (NUVL) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KROS | 438.1M | 11.77 | 5.12 | 67.75% | 35.65% | 14.25% | 24.19% | 0.06 |
 TPST | 59.99M | 2.15 | -1.43 | -5.68% | 0.80 | |||
 MRUS | 6.83B | 90.00 | -26.87 | -12.38% | -6.54% | -50.62% | 0.02 | |
 ERAS | 2.83B | 9.99 | -14.48 | -36.7% | 0.12 | |||
 TARS | 2.77B | 65.04 | -40.91 | 146.71% | -14.72% | -19.34% | 0.27 | |
 PRAX | 7.5B | 333.30 | -24.73 | -100% | -58.74% | 0.00 | ||
 KRYS | 8.38B | 284.57 | 41.60 | 33.94% | 53.92% | 19.25% | 2.26% | 0.01 |
 ARVN | 678.63M | 10.61 | -8.29 | -0.3% | -30.77% | -14.25% | 0.02 |
Compare NUVL vs Peers
Nuvalent, Inc. (NUVL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NUVL Income Statement
Nuvalent, Inc. (NUVL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - |
| Operating Expenses | 10.36M | 16.91M | 45.82M | 86.11M | 149.49M | 280.37M | 398.38M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 612K | 1.5M | 10.26M | 22.38M | 36.25M | 62.59M | 89.78M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 9.75M | 15.4M | 35.56M | 63.73M | 113.24M | 217.77M | 308.6M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -10.36M▲ 0% | -16.91M▼ 63.2% | -45.82M▼ 171.0% | -86.11M▼ 87.9% | -149.49M▼ 73.6% | -280.37M▼ 87.5% | -398.38M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -63.21% | -171.03% | -87.94% | -73.61% | -87.55% | - |
| EBITDA | 0 | -16.91M | -45.82M | -86.11M | -126.22M | 0 | -407.99M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | -171.03% | -87.94% | -46.58% | 100% | -69.64% |
| D&A (Non-Cash Add-back) | 10.36M | 0 | 0 | 0 | 0 | 280.37M | 0 |
| EBIT | -11.81M | -16.91M | -45.82M | -86.11M | -126.22M | -280.37M | -407.99M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 38.32M | 46.17M |
| Interest Income | 0 | 0 | 0 | 0 | 23.27M | 38.32M | 46.17M |
| Interest Expense | 0 | 0 | 0 | 0 | 23.27M | 0 | 0 |
| Other Income/Expense | -1.45M | 2.35M | -521K | 4.25M | 23.27M | 20.38M | 17.55M |
| Pretax Income | -11.81M▲ 0% | -14.56M▼ 23.3% | -46.34M▼ 218.3% | -81.85M▼ 76.6% | -126.22M▼ 54.2% | -259.99M▼ 106.0% | -380.83M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 764K | 605K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | -0.29% | -0.16% |
| Net Income | -11.81M▲ 0% | -14.56M▼ 23.3% | -46.34M▼ 218.3% | -81.85M▼ 76.6% | -126.22M▼ 54.2% | -260.76M▼ 106.6% | -381.44M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -23.26% | -218.34% | -76.65% | -54.2% | -106.59% | -70.07% |
| Net Income (Continuing) | -11.81M | -14.56M | -46.34M | -81.85M | -126.22M | -260.76M | -381.44M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.24▲ 0% | -0.64▼ 166.7% | -2.13▼ 232.8% | -1.65▲ 22.5% | -2.17▼ 31.5% | -3.93▼ 81.1% | -5.29▲ 0% |
| EPS Growth % | - | -166.67% | -232.81% | 22.54% | -31.52% | -81.11% | -53.31% |
| EPS (Basic) | -0.24 | -0.64 | -2.13 | -1.65 | -2.17 | -3.93 | - |
| Diluted Shares Outstanding | 48.28M | 22.86M | 21.78M | 49.67M | 58.22M | 66.41M | 72.14M |
| Basic Shares Outstanding | 48.28M | 22.86M | 21.78M | 49.67M | 58.22M | 66.41M | 72.14M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
NUVL Balance Sheet
Nuvalent, Inc. (NUVL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.32M | 10.65M | 290.63M | 477.99M | 726.49M | 1.13B | 956.95M |
| Cash & Short-Term Investments | 3.02M | 10.33M | 288.11M | 472.16M | 719.9M | 1.12B | 943.1M |
| Cash Only | 3.02M | 10.33M | 68.53M | 241.81M | 335.39M | 145.69M | 115.75M |
| Short-Term Investments | 0 | 0 | 219.59M | 230.36M | 384.52M | 972.61M | 827.35M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 314K | 0 | 5.83M | 6.58M | 14.15M | 13.84M |
| Total Non-Current Assets | 0 | 0 | 3.2M | 4.47M | 5.9M | 9.3M | 22.96M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 3.2M | 4.47M | 5.9M | 9.3M | 72.45M |
| Total Assets | 3.32M▲ 0% | 10.65M▲ 221.0% | 293.82M▲ 2659.9% | 482.46M▲ 64.2% | 732.38M▲ 51.8% | 1.14B▲ 55.9% | 979.91M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 221.05% | 2659.95% | 64.2% | 51.8% | 55.9% | 148.51% |
| Total Current Liabilities | 4.35M | 4.38M | 8.79M | 19.48M | 31.82M | 54.02M | 89.15M |
| Accounts Payable | 723K | 1.25M | 2.89M | 7.2M | 9.27M | 5.22M | 22.01M |
| Days Payables Outstanding | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | -3.15M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.46M | 2.59M | 3.16M | 7.43M | 7.33M | 0 | 67.14M |
| Current Ratio | 0.76x | 2.43x | 33.07x | 24.54x | 22.83x | 20.96x | 20.96x |
| Quick Ratio | 0.76x | 2.43x | 33.07x | 24.54x | 22.83x | 20.96x | 20.96x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 16.22M | 37.59M | 0 | 0 | 0 | 17.94M | 45.36M |
| Long-Term Debt | 2.17M | 2.23M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 14.05M | 35.35M | 0 | 0 | 0 | 17.94M | 108.67M |
| Total Liabilities | 20.57M | 41.97M | 8.79M | 19.48M | 31.82M | 71.96M | 134.51M |
| Total Debt | 2.17M | 2.23M | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -843K | -8.1M | -68.53M | -241.81M | -335.39M | -145.69M | -115.75M |
| Debt / Equity | - | - | - | - | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | 0.28x |
| Interest Coverage | - | - | - | - | -6.42x | - | - |
| Total Equity | -17.26M▲ 0% | -31.32M▼ 81.5% | 285.04M▲ 1010.0% | 462.98M▲ 62.4% | 700.56M▲ 51.3% | 1.07B▲ 52.7% | 845.4M▲ 0% |
| Equity Growth % | - | -81.52% | 1009.99% | 62.43% | 51.32% | 52.7% | 125.41% |
| Book Value per Share | -0.36 | -1.37 | 13.08 | 9.32 | 12.03 | 16.11 | 11.72 |
| Total Shareholders' Equity | -17.26M | -31.32M | 285.04M | 462.98M | 700.56M | 1.07B | 845.4M |
| Common Stock | 0 | 0 | 5K | 6K | 7K | 8K | 8K |
| Retained Earnings | -17.33M | -31.89M | -78.22M | -160.08M | -286.3M | -547.05M | -853.72M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -14.05M | -280K | -228K | -494K | 31K | -59K | 2.37M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NUVL Cash Flow Statement
Nuvalent, Inc. (NUVL) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.64M | -14.95M | -40M | -64.97M | -99.74M | -185.06M | -185.06M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -55.09% | -167.58% | -62.43% | -53.51% | -85.55% | -297.04% |
| Net Income | -11.81M | -14.56M | -46.34M | -81.85M | -126.22M | -260.76M | -381.44M |
| Depreciation & Amortization | 0 | 0 | 215K | -373K | 0 | 0 | 0 |
| Stock-Based Compensation | 41K | 729K | 3.55M | 10.32M | 25.56M | 60.58M | 58.59M |
| Deferred Taxes | 0 | 0 | -215K | -5.74M | 0 | 0 | 0 |
| Other Non-Cash Items | 1.57M | -2.39M | 846K | 5.74M | -10.11M | 3.27M | 37.05M |
| Working Capital Changes | 562K | 1.27M | 1.94M | 6.93M | 11.03M | 11.84M | 21.91M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 424K | 529K | 1.64M | 4.21M | 2.17M | -4.05M | 6.16M |
| Cash from Investing | 0 | 0 | -220.03M | -10.66M | -143.53M | -573.51M | -13.18M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 0 | 22.27M | 318.22M | 248.92M | 336.85M | 568.88M | 23.57M |
| Debt Issued (Net) | 0 | -250K | 284K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 4M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 15K | -3.98M | 286K | 12.55M | -1.1M | -301K |
| Net Change in Cash | -9.64M▲ 0% | 7.32M▲ 175.9% | 58.19M▲ 695.4% | 173.28M▲ 197.8% | 93.58M▼ 46.0% | -189.7M▼ 302.7% | -253.49M▲ 0% |
| Free Cash Flow | -9.64M▲ 0% | -14.95M▼ 55.1% | -40M▼ 167.6% | -64.97M▼ 62.4% | -99.74M▼ 53.5% | -185.06M▼ 85.5% | -263.88M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -55.09% | -167.58% | -62.43% | -53.51% | -85.55% | -72.16% |
| FCF per Share | -0.20 | -0.65 | -1.84 | -1.31 | -1.71 | -2.79 | -2.79 |
| FCF Conversion (FCF/Net Income) | 0.82x | 1.03x | 0.86x | 0.79x | 0.79x | 0.71x | 0.69x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NUVL Key Ratios
Nuvalent, Inc. (NUVL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -36.53% | -21.89% | -21.7% | -29.46% | -45.12% |
| Return on Invested Capital (ROIC) | - | -38.81% | -29.51% | -38.24% | -32.62% | -32.62% |
| Debt / Equity | - | - | - | - | - | 0.00x |
| Interest Coverage | - | - | - | -6.42x | - | - |
| FCF Conversion | 1.03x | 0.86x | 0.79x | 0.79x | 0.71x | 0.69x |
NUVL SEC Filings & Documents
Nuvalent, Inc. (NUVL) SEC filings — annual & quarterly reports (10-K, 10-Q)
NUVL Frequently Asked Questions
Nuvalent, Inc. (NUVL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nuvalent, Inc. (NUVL) grew revenue by 0.0% over the past year. Growth has been modest.
Nuvalent, Inc. (NUVL) reported a net loss of $381.4M for fiscal year 2024.
Dividend & Returns
Nuvalent, Inc. (NUVL) has a return on equity (ROE) of -29.5%. Negative ROE indicates the company is unprofitable.
Nuvalent, Inc. (NUVL) had negative free cash flow of $263.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More NUVL
Nuvalent, Inc. (NUVL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates